

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2022-23

Date: 26.05.2022

To

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Company Number: 531146

Sub. : Copy of Publication for Audited Financial Results for the quarter and year ended
March 31, 2022

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Audited Financial Results of the Company for the quarter and year ended on March 31, 2022 approved by the Board of Directors at their Meeting held on 25.05.2022.

The copy of the results published in the Financial Express and Jansatta dated May 26, 2022 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS-44157



Encl: As above.

ND FLOOR WITH ROOF RIGHTS, NAGAR COLONY, BEHIND HOLY PARTICULARLY DESCRIBED IN TANUSH GARG., PROPERTY, NORTH : OTHER'S

ices, we are hereby effecting service of by called upon u/s 13(2) of the Act to which the TCFSL will be exercising all or to notice that as per the terms of Section d secured assets.

Sd/- Authorised Officer
Capital Financial Services Limited

W/O Shri Dinesh Chandra R/O House No. 23 Seeta Vihar, Vill. Chandan, Lucknow, U.P. 226016. A/c Number : 2956182126

02.07.2021 Rs. 8,94,982/- + intt. w.e.f. 02.07.2021 & other charges 13(4) Amount Rs. 8,52,482/- + intt. w.e.f. 02.07.2021 & other charges

Situated At plot of Land No. 351, Area 112.45 sq mtr., Village Chandan, Ward Indira Priyadarshini, Tah and Distt Lucknow owned by Mr Dinesh Chandra. Bounded by : EAST-Plot of Arazi Deegar, WEST-Plot of new Seema Sahkari Awas Samiti, NORTH-18 feet wide road, SOUTH-Plot of Dohrey.

Date : 26.05.2022 Place : Lucknow Authorized Officer, Central Bank of India

Highway Limited

(6) Rakhamba Road, New Delhi 110001 7490000

Year Ended March 31, 2022

(Rs. Lakh) except per share data and Ratios

Particulars	Current Year Ended 31/03/2022	Previous Year Ended 31/03/2021
Operating Profit	49,685.09	31,640.21
Operating Loss	18,957.47	7,982.84
Operating Profit	18,957.47	7,982.84
Operating Loss	18,957.47	8,845.96
Operating Profit	18,957.37	8,846.57
Operating Loss	791.44	791.44
Operating Profit	47,629.66	33,163.59
Operating Loss	16,108.60	16,108.60
Operating Profit	26,223.48	7,266.11
Operating Loss	1,86,878.79	2,00,854.13
Operating Profit	11.88	11.88
Operating Loss	239.53	111.77
Operating Profit	239.53	111.77
Operating Profit	18,750.00	14,258.69
Operating Loss	1.15	0.87
Operating Profit	2.06	1.42

Medicamen Biotech Ltd.
Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN: L74899DL1993PLC056594
E-mail: cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31.03.2022

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2022	Audited 31.03.2021	Audited 31.03.2022	Audited 31.03.2021	Audited 31.03.2022	Audited 31.03.2021
1	Total income from operations (net)	2309.14	2087.46	11716.53	11090.06	11716.53	11347.01
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	322.84	464.35	1810.35	1675.12	1809.42	1639.40
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	322.84	464.35	1810.35	1675.12	1809.42	1639.40
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	275.47	414.34	1490.64	1248.66	1489.71	1212.94
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax)}	275.47	414.34	1490.64	1248.66	1489.71	1212.94
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)						
	Basic:	2.25	3.39	12.20	10.22	12.19	9.93
	Diluted:	2.25	3.39	12.20	10.22	12.19	9.93

Note:

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 25th May 2022. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure-Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarters ended March 31, 2022 and March 31, 2021 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figures upto the period end of the third quarter of the relevant financial year, which were subject to limited review.
- The board of Directors has recommended a dividend @ 10% i.e Rs. 1 per share (Face value INR 10 per share) subject to approval of members in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- Audit report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place: New Delhi
Date : 25.05.2022

For Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Chairman

The Board of Directors of the Company at its results filed with the Stock Exchanges under Regulations, 2015, as amended. The full websites of the Stock Exchange(s) at and Disclosure Requirements) Regulations, Stock Exchange of India Limited and can be a difference between audited figures for the December 31, 2021 and December 31, 2020 classified wherever necessary, to make them

P Jammu Udampur Highway Limited
Sd/-
Mukundan Srinivasan
Director
DIN: 00276429

No.	
1	Total
2	Net P
3	(befor
4	Net P
5	Total
6	Paid u
7	Reser
8	Secur
9	Net w
10	Paid u
11	Outst
12	Debt
13	Earnin
	(not a
	Basic
	Dilute
14	Capit
15	Debe
16	Debt
17	Inter

* Exemptio	Sr. No.	
	1	Total
	2	Net P
	3	(befor
	4	Net P
	5	Total
	6	Paid u
	7	Reser
	8	Secur
	9	Net w
	10	Paid u
	11	Outst
	12	Debt
	13	Earnin
		(not a
		Basic
		Dilute
	14	Capit
	15	Debe
	16	Debt
	17	Inter

Notes:

- The ab
- Exchar
- 2015.
- Exchar
- pvt-ltd/
- 2015.
- For the
- Require
- Ltd.) a
- trading
- 3 The co
- Indian,
- 133 of
- amend
- 4 The ab
- Obliga
- record
- 5 Previo

Place: Mu
Date - 24th



Medicamen Biotech Ltd.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN: L74899DL1993PLC056594
E-mail: cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31.03.2022

(In Lakhs)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2022	Audited 31.03.2021	Audited 31.03.2022	Audited 31.03.2021	Audited 31.03.2022	Audited 31.03.2021
1	Total income from operations (net)	2309.14	2087.46	11716.53	11090.06	11716.53	11347.01
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	322.84	464.35	1810.35	1675.12	1809.42	1639.40
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	322.84	464.35	1810.35	1675.12	1809.42	1639.40
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	275.47	414.34	1490.64	1248.66	1489.71	1212.94
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	275.47	414.34	1490.64	1248.66	1489.71	1212.94
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)						
	Basic:	2.25	3.39	12.20	10.22	12.19	9.93
	Diluted:	2.25	3.39	12.20	10.22	12.19	9.93

Note:

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 25th May 2022. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarters ended March 31, 2022 and March 31, 2021 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figures upto the period end of the third quarter of the relevant financial year, which were subject to limited review.
- The board of Directors has recommended a dividend @ 10% i.e Rs. 1 per share (Face value INR 10 per share) subject to approval of members in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earning per Share".
- Audit report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date: 25.05.2022

अनडिलिवर्ड डिमांड नोटिस

का विवरण रबीड / रजिस्टर्ड पोस्ट द्वारा डिमांड नोटिस भेजने की तारीख: 21.05.2022
दिनांक 13 का भाग, बेनीपुर वर्गमीटर, संपत्ति श्री अदुल के नाम। सीमायें:- उत्तर: अराजी जाने आलम, पूर्व: र अली
डिमांड नोटिस की तारीख: 19.05.2022
नोटिस के अनुसार देय राशि
₹ 901895.18 + ब्याज व अन्य खर्च दिनांक 01.05.2022 से

सिक्वोरिटी इन्स्ट्रुमेंट एक्ट 2002 के अन्तर्गत तथा सिक्वोरिटी इन्स्ट्रुमेंट्स अधिनियम 1999 के अन्तर्गत प्राधिकृत अधिकारी ने सम्बन्धित राशि अदा करने के लिए मांग नोटिस जारी किया था, जो बैंक की शाखा पर किया। आपको सूचित किया जाता है कि आप वापस आये नोटिस को

अन्यथा बैंक (secured creditor) वित्तीय आस्तियों का प्रतिभूतिकरण त शक्तियों अथवा किसी एक शक्ति का प्रयोग करने का अधिकारी होगा।

प्राधिकृत अधिकारी

: 913, Hemkunt Chambers, 89 Nehru Place, - 110 019, CIN : L74210DL1971PLC005712
el : +91-11-2641-1931 / 2641-5961

AR ENDED 31ST MARCH 2022

EPS	CONSOLIDATED		(Rs.in Lacs except shares and EPS)	
	Quarter Ended	Year Ended	Quarter Ended	Year Ended
ended	31.03.2022	31.03.2022	31.03.2021	31.03.2021
ed)	(Audited)	(Audited)	(Audited)	(Audited)
90	4,260.83	11,294.32	1,032.19	2,662.90
92	(2,594.55)	(4,767.44)	(392.92)	(8,403.83)
32	(2,594.55)	(7,999.30)	(1,047.38)	(12,775.23)
32	(2,595.18)	(8,000.71)	(1,052.34)	(12,785.21)
32	(2,595.18)	(8,000.71)	(1,052.34)	(12,785.21)
44	(2,574.87)	(7,979.52)	(1,039.17)	(12,779.33)
00	1,049.00	1,049.00	1,049.00	1,049.00
79		(19,986.83)		(12,007.31)
2)	(24.74)	(76.27)	(10.03)	(121.88)
2)	(24.74)	(76.27)	(10.03)	(121.88)

Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and also

on behalf of the Board of Directors of Technofab Engineering Limited
Sd/- Arjun Gupta (Chairman & Managing Director) DIN-00012092

sbil.05169@sbi.co.in

के अधीन अचल सम्पत्तियों के विक्रय हेतु ई-नीलामी विक्रय नोटिस प्रक/ गिरवी/ प्रभारित है, का कब्जा, (प्रतिभूत लेनदार) के प्राधिकृत (क) से - प्रतिभूत लेनदार की नीचे वर्णित रूपरेखा की बकाया राशि की

संपर्क हेतु व्यक्ति का नाम और नं.	ई-नीलामी की तिथि प्रत्येक 5 मिनट के असीमित विस्तार के साथ	सम्पत्ति का स्थल पर निरीक्षण करने हेतु तिथि एवं समय:
रम कु. श्रीवास्तव 8283955009 & डी.एस बिष्ट नं. 9971846693	28-06-2022 दोपहर 12.00 बजे से अपरा. 04.00 बजे तक	15-06-2022 पूर्वाह्न 11.00 बजे से अपरा. 03.00 बजे तक
रम कु. श्रीवास्तव 8283955009 & डी.एस बिष्ट नं. 9971846693	28-06-2022 दोपहर 12.00 बजे से अपरा. 04.00 बजे तक	15-06-2022 पूर्वाह्न 11.00 बजे से अपरा. 03.00 बजे तक

ecommerce.com/auctionhome/ibapi/index.jsp के माध्यम से अथवा ibapi के ई-नीलामी प्लेटफॉर्म <https://ibapi.in> &

हम (सि) के स्वाभिल तथा सम्पत्तियों को प्रभावित करने वाले दावों / कर्तव्यों/ वचनबद्धता निर्मित नहीं करता है और न ही कोई वचनबद्धता के दावों / अधिकारों/ बकाया राशियों के लिए किसी भी तरह से

वेबसाइट में इस तरह की जानकारी को अपडेट करने के बाद ही दी है कि किसी भी अंतिम समय की समस्या से बचने के लिए बोली

दिल्ली जल बोर्ड: रा.रा. क्षेत्र दिल्ली सरकार

कार्यालय: अति. मुख्य अभियंता (एम) -11
कमरा सं. 110, पुराना शिव मंदिर मार्ग, जल सदन,
लाजपत नगर, नई दिल्ली-110024
ईमेल: eedjbm11@gmail.com, फोन: 011-29810956



क्र.सं.	कार्य का विवरण	व्यय (₹. में)	ई-प्रापण सॉल्यूशन के माध्यम से निविदा जारी की तिथि	ई-प्रापण सॉल्यूशन के माध्यम से प्रापण की अंतिम तिथि/समय
1.	राजस्व निर्माण के लिये डि.ज.बो. की विभिन्न भूमि के पुनर्विकास के लिये व्यापक आर्किटेक्चरल परामर्श सेवाओं का प्रावधान।	1,10,00,000/-	2022 DJB 222950_1 25.5.2022	14.6.2022 के 3.00 बजे अप. त

इस संदर्भ में सभी नियमों एवं शर्तों सहित एनआईटी के अधिक विवरण वेबसाइट <https://govtprocurement.delhi.gov.in> पर देखें।

पी.आर.ओ. (जल) द्वारा जारी
विज्ञा. सं. जे.एस.बी. 140 (2022-23)

(नेशनल कुमार क...
कार्यालयक अभियंता (टी) ए

"कोरोना रोकें, मास्क पहनें, शारीरिक दूरी का पालन करें, हाथों को स्वच्छ रखें"

दिल्ली जल बोर्ड: रा.रा. क्षेत्र दिल्ली सरकार

कार्यालय: अति. मुख्य अभियंता एम-3, उप अधीक्षण अभियंता (टी) एम-3